Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Aβ Peptide

  • Daniel Paris
  • Nikunj Patel
  • Nowell J. Ganey
  • Vincent Laporte
  • Amita Quadros
  • Michael J. Mullan
Article

Abstract

The inhibition of angiogenesis is regarded as a promising avenue for cancer treatment. Although some antiangiogenic compounds are in the process of development and testing, these often prove ineffective in vivo, therefore the search for new inhibitors is critical. We have recently identified a ten amino acid fragment of the Alzheimer Aβ peptide that is anti-angiogenic both in vitro and in vivo. In the present study, we investigated the antitumoral potential of this decapeptide using human MCF-7 breast carcinoma xenografts in nude mice. We observed that this decapeptide was able to suppress MCF-7 tumor growth more potently than the antiestrogen tamoxifen. Inhibition of tumor vascularization as determined by PECAM-1 immunostaining and decreased tumor cell proliferation as determined by Ki67 immunostaining were observed following treatment with the Aβ fragment. In vitro, this peptide had no direct impact on MCF-7 tumor cell proliferation and survival suggesting that the inhibition of tumor growth and tumor cell proliferation observed in vivo is related to the antiangiogenic activity of the peptide. Taken together these data suggest that this short Aβ derivative peptide may constitute a new antitumoral agent.

Keywords

Breast cancer Aβ peptides Alzheimer Angiogenesis Tumor xenograft MCF-7 

References

  1. Abdullah L, Paris D, Luis C, Quadros A, Parrish J, Valdes L, Keegan AP, Mathura V, Crawford F, Mullan M (2007) The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. Neurosci Lett 428(2–3):53–58CrossRefPubMedGoogle Scholar
  2. Abdullah L, Luis C, Paris D, Ait-ghezala G, Mouzon B, Allen E, Parrish J, Mullan MA, Ferguson S, Wood M, Crawford F, Mullan M (2009) High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer’s disease patients. Mol Med 15(3–4):95–100PubMedGoogle Scholar
  3. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P (2008) Conversion from cognitive health to mild cognitive impairment and Alzheimer’s disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging 29(1):1–11CrossRefPubMedGoogle Scholar
  4. Clarke R, Leonessa F, Welch JN, Skaar TC (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53(1):25–71PubMedGoogle Scholar
  5. Daniel CP, Gaskell SJ, Bishop H, Nicholson RI (1979) Determination of tamoxifen and a hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography-mass spectrometry. J Endocrinol 83(3):401–408CrossRefPubMedGoogle Scholar
  6. Deane R, Zlokovic BV (2007) Role of the blood-brain barrier in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 4(2):191–197CrossRefPubMedGoogle Scholar
  7. DeSouky AL (1992) The relationship between cancer and Alzheimer’s disease. J Am Geriatr Soc 40(10):1075PubMedGoogle Scholar
  8. Donnini S, Cantara S, Morbidelli L, Giachetti A, Ziche M (2006) FGF-2 overexpression opposes the beta amyloid toxic injuries to the vascular endothelium. Cell Death Differ 13(7):1088–1096CrossRefPubMedGoogle Scholar
  9. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, Salter J, Detre J, Hills M, Walsh G (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99(2):167–170CrossRefPubMedGoogle Scholar
  10. Drago D, Folin M, Baiguera S, Tognon G, Ricchelli F, Zatta P (2007) Comparative effects of Abeta(1–42)-Al complex from rat and human amyloid on rat endothelial cultures. J Alzheimers Dis 11(1):33–44PubMedGoogle Scholar
  11. Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8785):71–85Google Scholar
  12. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N (2005) Tamoxifen for the prevention of breast cancer: current status of the national Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652–1662PubMedCrossRefGoogle Scholar
  13. Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST (2005) Alzheimer disease and mortality. A 15-year epidemiological study. Arch Neurol 62(5):779–784CrossRefPubMedGoogle Scholar
  14. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2):101–112CrossRefPubMedGoogle Scholar
  15. Howell A, Dodwell DJ, Anderson H (1990) New endocrine approaches to breast cancer. Baillieres Clin Endocrinol Metab 4(1):67–84CrossRefPubMedGoogle Scholar
  16. Lehnes K, Winder AD, Alfonso C, Kasid N, Simoneaux M, Summe H, Morgan E, Iann MC, Duncan J, Eagan M, Tavaluc R, Evans CH Jr, Russell R, Wang A, Hu F, Stoica A (2007) The effect of estradiol on in vivo tumorigenesis is modulated by the human epidermal growth factor receptor 2/phosphatidylinositol 3-kinase/Akt1 pathway. Endocrinology 148(3):1171–1180CrossRefPubMedGoogle Scholar
  17. Matsuda H, Mizumura S, Nagao T, Ota T, Iizuka T, Nemoto K, Takemura N, Arai H, Homma A (2007) Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography. Am J Neuroradiol 28(4):731–736PubMedGoogle Scholar
  18. Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T (2008) Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer’s disease. Proc Natl Acad Sci USA 105(9):3587–3592CrossRefPubMedGoogle Scholar
  19. Osborne CK (1998) Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51(3):227–238CrossRefPubMedGoogle Scholar
  20. Paris D, Humphrey J, Quadros A, Patel N, Crescentini R, Crawford F, Mullan M (2003) Vasoactive effects of Abeta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer’s disease: role of inflammation. Neurol Res 25(6):642–651CrossRefPubMedGoogle Scholar
  21. Paris D, Patel N, DelleDonne A, Quadros A, Smeed R, Mullan M (2004a) Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett 366(1):80–85CrossRefPubMedGoogle Scholar
  22. Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, Sebti SM, Mullan M (2004b) Inhibition of angiogenesis by Abeta peptides. Angiogenesis 7(1):75–85CrossRefPubMedGoogle Scholar
  23. Paris D, Ait-Ghezala G, Mathura VS, Patel N, Quadros A, Laporte V, Mullan M (2005) Anti-angiogenic activity of the mutant Dutch Abeta peptide on human brain microvascular endothelial cells. Brain Res Mol Brain Res 136(1–2):212–230CrossRefPubMedGoogle Scholar
  24. Patel NS, Quadros A, Brem S, Wotoczek-Obadia M, Mathura VS, Laporte V, Mullan M, Paris D (2008) Potent antiangiogenic motifs within the Alzheimer beta-amyloid peptide. Amyloid 15(1):5–19CrossRefPubMedGoogle Scholar
  25. Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL (2008) Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71(2):85–92CrossRefPubMedGoogle Scholar
  26. Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC (2005) Alzheimer disease and cancer. Neurology 64(5):895–898PubMedGoogle Scholar
  27. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87(9):645–651CrossRefPubMedGoogle Scholar
  28. Solito R, Corti F, Fossati S, Mezhericher E, Donnini S, Ghiso J, Giachetti A, Rostagno A, Ziche M (2009) Dutch and Arctic mutant peptides of beta amyloid(1–40) differentially affect the FGF-2 pathway in brain endothelium. Exp Cell Res 315(3):385–395CrossRefPubMedGoogle Scholar
  29. Tirumalasetti F, Han L, Birkett DP (1991) The relationship between cancer and Alzheimer’s disease. J Am Geriatr Soc 39(8):840PubMedGoogle Scholar
  30. van Diest PJ, van der Wall E, Baak JP (2004) Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 57(7):675–681CrossRefPubMedGoogle Scholar
  31. Watson D, Castaño E, Kokjohn TA, Kuo YM, Lyubchenko Y, Pinsky D, Connolly ES Jr, Esh C, Luehrs DC, Stine WB, Rowse LM, Emmerling MR, Roher AE (2005) Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer’s disease. Neurol Res 27(8):869–881CrossRefPubMedGoogle Scholar
  32. Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, Liu D, Li F, Armstrong D, Gasiewicz T, Zidovetzki R, Song X, Hofman F, Zlokovic BV (2005) Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 11(9):959–965PubMedGoogle Scholar
  33. Yamada M, Sasaki H, Mimori Y, Kasagi F, Sudoh S, Ikeda J, Hosoda Y, Nakamura S, Kodama K (1999) Prevalence and risks of dementia in the Japanese population: RERF’s adult health study Horoshima subjects. Radiation Effects Research Foundation. J Am Geriatr Soc 47(2):189–195PubMedGoogle Scholar
  34. Yashin AI, Ukraintseva SV, Akushevich IV, Arbeev KG, Kulminski A, Akushevich L (2009) Trade-off between cancer and aging: what role do other diseases play?. Evidence from experimental and human population studies. Mech Ageing Dev 130(1–2):98–104CrossRefPubMedGoogle Scholar
  35. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci 28(4):202–208CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Daniel Paris
    • 1
  • Nikunj Patel
    • 1
  • Nowell J. Ganey
    • 1
  • Vincent Laporte
    • 1
  • Amita Quadros
    • 1
  • Michael J. Mullan
    • 1
  1. 1.The Roskamp InstituteSarasotaUSA

Personalised recommendations